Completed Enrollment

A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer (eMonarcHER)

The main purpose of this study is to measure how well abemaciclib works in participants with early breast cancer who are taking hormone therapy after surgery. Participants must have breast cancer that is hormone receptor positive (HR+) and human epidermal receptor 2 positive (HER2+).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Breast Cancer
What the trial is testing?
Abemaciclib Plus Hormone Therapy
Could I receive a Placebo?
Yes
Enrollment Goal
2450
Trial Dates
May 10, 2021 - Jun 2024
How long will I be in the trial?
Your participation could last up to 10 years depending on how you and your tumor respond.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have confirmed hormone receptor positive (HR+), human epidermal receptor 2 positive (HER2+) breast cancer

  • Participants must have had surgery for this breast cancer

  • Participants must have had chemotherapy and therapy targeted for HER2+ breast cancer

  • Female participant of child-bearing potential must agree to use highly effective birth control methods

  • Participants must be able to swallow oral medications

Participants Must Not:

  • Female participant must not be pregnant or breastfeeding

  • Participants must not have breast cancer that has spread to another part(s) of the body

  • Participants must not have received an experimental treatment in a clinical trial within the last 30 days

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources